| Item Type | Name |
|
Academic Article
|
The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer.
|
|
Concept
|
Carcinoma, Ductal
|
|
Concept
|
Carcinoma, Ductal, Breast
|
|
Academic Article
|
Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome.
|
|
Academic Article
|
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast.
|
|
Academic Article
|
Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer.
|
|
Academic Article
|
Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer.
|
|
Academic Article
|
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass.
|
|
Academic Article
|
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer.
|
|
Academic Article
|
Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death.
|
|
Academic Article
|
Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype.
|
|
Academic Article
|
Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node.
|
|
Academic Article
|
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision.
|
|
Academic Article
|
American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns.
|
|
Academic Article
|
Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial.
|
|
Academic Article
|
Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy.
|
|
Academic Article
|
Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted?
|
|
Academic Article
|
Impact of identification of internal mammary sentinel lymph node metastasis in breast cancer patients.
|
|
Academic Article
|
Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy.
|
|
Academic Article
|
Does blue dye contribute to success of sentinel node mapping for breast cancer?
|
|
Academic Article
|
Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer.
|
|
Academic Article
|
Predicting the extent of nodal disease in early-stage breast cancer.
|
|
Academic Article
|
Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial.
|
|
Academic Article
|
Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ?
|
|
Academic Article
|
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
|
|
Academic Article
|
Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients.
|
|
Academic Article
|
Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).
|
|
Academic Article
|
Trends and controversies in multidisciplinary care of the patient with breast cancer.
|
|
Academic Article
|
Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS).
|
|
Academic Article
|
SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer.
|
|
Academic Article
|
Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis.
|
|
Academic Article
|
Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
|
|
Academic Article
|
A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer.
|
|
Academic Article
|
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
|
|
Academic Article
|
Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer.
|
|
Academic Article
|
Multidisciplinary considerations in the treatment of triple-negative breast cancer.
|
|
Academic Article
|
Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer.
|
|
Academic Article
|
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ.
|